Biocardia Average Payables from 2010 to 2024
| BCDA Stock | USD 2.19 0.09 3.95% |
Average Payables | First Reported 2010-12-31 | Previous Quarter 6.8 K | Current Value 6.4 K | Quarterly Volatility 54.9 K |
Check Biocardia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocardia's main balance sheet or income statement drivers, such as Depreciation And Amortization of 79.8 K, Interest Expense of 6.6 K or Selling General Administrative of 3.3 M, as well as many indicators such as Price To Sales Ratio of 28.01, Dividend Yield of 0.27 or Days Sales Outstanding of 45.8. Biocardia financial statements analysis is a perfect complement when working with Biocardia Valuation or Volatility modules.
Biocardia | Average Payables |
Latest Biocardia's Average Payables Growth Pattern
Below is the plot of the Average Payables of Biocardia over the last few years. It is the average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers. Biocardia's Average Payables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biocardia's overall financial position and show how it may be relating to other accounts over time.
| Average Payables | 10 Years Trend |
|
Average Payables |
| Timeline |
Biocardia Average Payables Regression Statistics
| Arithmetic Mean | 20,167 | |
| Geometric Mean | 7,607 | |
| Coefficient Of Variation | 272.27 | |
| Mean Deviation | 26,464 | |
| Median | 5,888 | |
| Standard Deviation | 54,908 | |
| Sample Variance | 3B | |
| Range | 212.8K | |
| R-Value | (0.43) | |
| Mean Square Error | 2.6B | |
| R-Squared | 0.19 | |
| Significance | 0.11 | |
| Slope | (5,286) | |
| Total Sum of Squares | 42.2B |
Biocardia Average Payables History
About Biocardia Financial Statements
Biocardia stakeholders use historical fundamental indicators, such as Biocardia's Average Payables, to determine how well the company is positioned to perform in the future. Although Biocardia investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biocardia's assets and liabilities are reflected in the revenues and expenses on Biocardia's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biocardia. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Average Payables | 6.8 K | 6.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out the analysis of Biocardia Correlation against competitors. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share 0.264 | Quarterly Revenue Growth (0.93) | Return On Assets (1.16) | Return On Equity (7.04) |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.